Trials / Completed
CompletedNCT01165242
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1,013 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 10 Years – 25 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this observer-blind study is to evaluate the safety and immunogenicity of GSK Biologicals' meningococcal vaccine GSK134612 as compared to Menactra® in subjects 10 through 25 years of age. In addition, this study will compare the immunogenicity of two lots of GSK 134612 vaccine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Meningococcal vaccine GSK 134612 | One intramuscular injection |
| BIOLOGICAL | Menactra® | One intramuscular injection |
Timeline
- Start date
- 2010-08-19
- Primary completion
- 2011-02-25
- Completion
- 2011-07-29
- First posted
- 2010-07-19
- Last updated
- 2018-06-26
- Results posted
- 2017-06-08
Locations
32 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT01165242. Inclusion in this directory is not an endorsement.